The third-generation aromatase inhibitors (AIs) letrozole, anastrozole and exemestane have become established in the care of ER+ breast cancer in the adjuvant setting due to their superiority over tamoxifen in postmenopausal patients with improved disease-free and overall survival [21, 22]. Here, ESR1 is linked to breast cancer.